A new study published in Mucosal Immunology shows that α-galactosylceramide (α-GalCer) serves as a potent adjuvant by activating natural killer T (NKT) cells, which promote effective cross ...

We confirmed this by IL-13 inhibitor (sIL-13Rα2–Fc) treatment. Loss of natural killer T cells (NKT cells) in CD1 knockout mice resulted in decreased IL-13 production and resistance to recurrence.